|

Multiple Sclerosis Clinical Trials in Dallas, TX

15 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerPhase 1<1 mi
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPhase 2<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisPhase 4<1 mi
NARCOMS Registry: A Multiple Sclerosis Registry—<1 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 3<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—<1 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 3<1 mi
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPhase 3<1 mi
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current StimulationN/A13 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 318 mi
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Phase 218 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Phase 326 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 331 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.